(C23) Clinical Outcomes Through 3 Months in Dogs with MMVD Treated with the TEER

Abstract:
Background – Transcatheter edge-to-edge repair (TEER) is an emerging treatment option for dogs with myxomatous valve disease (MMVD) but reports on the effectiveness and safety of TEER are lacking.
Hypothesis/Objectives – To report the clinical outcomes through 3 months in four dogs with MMVD with TEER.Animals –Four client-owned dogs undergoing TEER. Methods – This retrospective study included four dogs treated with TEER using the V-clamp® device. The following data were obtained from the medical records for analyses: history, clinical signs, body weight, complete blood count, serum chemistry, venous blood gas analysis, cardiac troponin I, NT-proBNP, thoracic radiography, and trans-thoracic echocardiography results.
Results – Two dogs were in advanced MMVD stage B2, one in MMVD stage C and one in MMVD stage D. Before the surgical procedure, pimobendan and furosemide were prescribed for all dogs. The median body weight was 3.68 kg (range, 2.44-6.28 kg). After the surgical procedure, all dogs exhibited a significant reduction in mitral regurgitation. Three dogs successfully discontinued diuretics whereas one dog required diuretics starting from the third month. No postoperative complications were observed during the three-month observation period.
Conclusions and clinical importance – TEER with the V-clamp® device showed promising short-term efficacy in managing myxomatous valve disease in dogs.